Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo

Zacks06-05

Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441325268?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","is_english":true,"pubTime":"2024-06-05 01:17","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2441325268","market":"us","top_or_hot":-1,"title":"Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo","media":"Zacks","content":"<div>\n<p>Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-bmy-reports-positive-171700225.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-05 01:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-bmy-reports-positive-171700225.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-bmy-reports-positive-171700225.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/bristol-myers-bmy-reports-positive-171700225.html","article_id":"2441325268","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441325268","pubTimestamp":1717521420,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi  at the 2024 American Society of Clinical Oncology  Annual Meeting.These data include long-term data with three-year follow-up from the late-stage TRANSFORM study of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma . These also include results from a subgroup analysis evaluating the efficacy and safety of Breyanzi by a number of prior lines of therapy in the mantle cell lymphoma  cohort of the TRANSCEND NHL 001 trial, and those from a subgroup analysis assessing the efficacy and safety of Breyanzi based on the use of bridging therapy in the TRANSCEND FL trial in relapsed or refractory follicular lymphoma .BMY also announced positive results from three updated analyses f","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","PFS":"Provident Financial Services Inc","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4532":"文艺复兴科技持仓","BK4161":"工业机械","CR":"crane","BK4585":"ETF&股票定投概念","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4534":"瑞士信贷持仓","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4139":"生物科技","LU0882574055.USD":"富达全球健康医疗A ACC","KRYS":"Krystal Biotech Inc.","BK4007":"制药","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4195":"互助储蓄与抵押信贷金融服务","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","ALXO":"ALX Oncology Holdings","FL":"富乐客","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4588":"碎股","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","NERV":"Minerva Neurosciences","BMY":"施贵宝","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4094":"服装零售","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0237698245.USD":"富达环球地产基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4581":"高盛持仓","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"百时美施贵宝(BMY)报告Breyanzi、Opdivo的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1,"NERV":1,"ALXO":1,"FL":1,"CR":1,"KRYS":1,"BMY":1},"content_text":"Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.\nThese data include long-term data with three-year follow-up from the late-stage TRANSFORM study of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL). These also include results from a subgroup analysis evaluating the efficacy and safety of Breyanzi by a number of prior lines of therapy in the mantle cell lymphoma (MCL) cohort of the TRANSCEND NHL 001 trial, and those from a subgroup analysis assessing the efficacy and safety of Breyanzi based on the use of bridging therapy in the TRANSCEND FL trial in relapsed or refractory follicular lymphoma (FL).\nThe three-year follow-up (at a median follow-up of 33.9 months) results from the TRANSFORM study showed sustained significant clinical benefit with continued improvements in the primary endpoint of event-free survival (EFS) with Breyanzi compared to standard of care (SoC) in LBCL patients. Clinical benefit was also observed in the secondary endpoints of progression-free survival (PFS), overall responses and duration of response (DOR) compared to SoC. The outcomes were consistent with the primary analysis results.\nThe MCL cohort of TRANSCEND NHL 001 enrolled adults with relapsed or refractory disease after two or more prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor. Results from a subgroup analysis from this cohort showed that Breyanzi demonstrated consistent clinical benefit, regardless of the number of prior lines of therapy. Breyanzi showed similar efficacy across most subgroups based on overall responses, complete responses (CR), median DOR, PFS and overall survival, including heavily-pretreated patients. The data supports the use of Breyanzi in earlier lines of treatment.\nData from bridging therapy subgroup analysis of TRANSCEND FL show consistent efficacy with high response rates and a consistent safety profile, regardless of receiving prior bridging therapy. The data supports Breyanzi’s differentiated profile in relapsed or refractory FL.\nLast week, Breyanzi was granted accelerated approval by the FDA for adult patients with relapsed or refractory FL, who have received two or more prior lines of systemic therapy. The FDA also granted Breyanzi approval for patients with relapsed or refractory MCL, who have received at least two prior lines of systemic therapy, including a BTK inhibitor, expanding its use to include four distinct types of B-cell lymphomas.\nThis FDA approval marks the fourth distinct subtype of non-Hodgkin lymphoma for which Breyanzi is approved.The new encouraging data at ASCO, which showed improved outcomes and consistent safety profile Breyanzi provides for diverse types of lymphoma patients, reinforced its potential and impressed investors.\nBMY also announced positive results from three updated analyses from the CheckMate -77T, CheckMate -816, and CheckMate -9LA studies supporting Opdivo (nivolumab) and Opdivo-based combinations in early-stage and advanced non-small cell lung cancer (NSCLC) at ASCO.\nThe late-breaking exploratory analysis of the CheckMate -77T study of perioperative Opdivo shows improved EFS and pathologic CR in stage III resectable NSCLC patients regardless of nodal status.\nFour-year follow-up data from the CheckMate -816 study reinforced treatment with neoadjuvant Opdivo, in combination with chemotherapy in patients with resectable NSCLC. Five-year follow-up data from the CheckMate -9LA study showed that Opdivo, plus Yervoy and chemotherapy, improves survival in patients with previously untreated metastatic NSCLC versus chemotherapy alone.\nThe company’s shares have lost 18.7% year to date compared with the industry's decline of 5.7%.\nImage Source: Zacks Investment Research\nOpdivo is one of the top drugs for BMY.  Last week, the European Commission approved Opdivo in combination with a chemotherapy combination, cisplatin and gemcitabine, as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma.\nApproval of new drugs and label expansion of the existing ones are imperative for BMY as it looks to expand its portfolio. One of the top drugs, Revlimid, is already facing generic competition, and Eliquis, too, is likely to face challenges later.\nHence, BMY is banking on Opdivo and newer drugs like Reblozyl and Opdualag to drive growth in the future.\nThe recent acquisitions of Mirati Therapeutics, Karuna Therapeutics, Inc. and RayzeBio should also aid the company’s efforts to expand its portfolio.\nZacks Rank & Stocks to Consider\nBristol Myers currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the healthcare sector are Krystal Biotech, Inc. KRYS, ALX Oncology Holdings ALXO and Minerva Neurosciences, Inc. NERV, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 30 days, the Zacks Consensus Estimate for KRYS’ earnings per share has increased 24 cents to $2.06. KRYS beat on earnings in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 21.46%. Shares of Krystal Biotech have surged 33.3% year to date.\nIn the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73.\nALX Oncology beat on earnings in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 8.83%.\nIn the past 60 days, estimates for Minerva Neurosciences’ 2024 loss per share have narrowed from $3.57 to $1.89. Loss per share estimate for 2025 has narrowed from $4.54 to $3.60. Year to date, shares of NERV have lost 52.8%.\nNERV’s earnings beat estimates in one of the trailing four quarters and missed the same in the other three, the average negative surprise being 54.43%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBristol Myers Squibb Company (BMY) : Free Stock Analysis Report\nMinerva Neurosciences, Inc (NERV) : Free Stock Analysis Report\nKrystal Biotech, Inc. (KRYS) : Free Stock Analysis Report\nALX Oncology Holdings Inc. (ALXO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441325268"}